Lung Cancer

Clinical advances in treatment of small cell lung cancer have lagged behind those of other tumor types, but the delay is not for lack of effort.

Jay Moon Lee, MD, discusses the current state of molecular testing in early-stage non–small cell lung cancer.

Sandip P. Patel, MD, discusses the utility of consolidative durvalumab in stage III non–small cell lung cancer.

The availability of chemoimmunotherapy combinations and targeted agents for common and rare mutations alike in non–small cell lung cancer has fostered discussions that might have been unthinkable just a decade or so ago.

The combination of sintilimab, a bevacizumab biosimilar injection, and chemotherapy resulted in a significant improvement in progression-free survival in patients with EGFR-mutated, nonsquamous, non–small cell lung cancer that as progressed following treatment with an EGFR TKI, meeting the primary end point of the phase 3 ORIENT-31 trial.

Ahmet Sezer, MD, discusses how the approval of cemiplimab could potentially make a huge impact for patients with advanced non–small cell lung cancer.

Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with ALK+ NSCLC. They also summarize recent clinical data for ALK inhibitors.

Ben Levy, Mark Socinski, and Stephen Liu explain the role of an ALK alteration in NSCLC and its value as a targetable biomarker.

Melissa L. Johnson, MD, discusses the emergence of datopotamab deruxtecan in non–small cell lung cancer with actionable genomic alterations.

The FDA has approved atezolizumab for use as an adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non–small cell lung cancer whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test.

M. Patricia Rivera, MD, a professor of medicine at The University of North Carolina at Chapel Hill, reviews the United States Preventive Services Task Force's lung cancer screening recommendations as of 2021, including the impacted patient populations and effect the recommendations have on direct physician care.

Andrea Borondy Kitts, a lung cancer and patient advocate at Rescue Lung Society, educates physicians on adequate physician-to-patient education and resources that improve their opportunity for success in lung cancer care.

Bob T. Li, MD, PhD, MPH, discusses the limitations of the phase 3 IMpower010 trial in resected stage IB to IIIA non–small cell lung cancer.

Jacob Sands, MD, a physician at Dana-Farber Cancer Institute, as well as an instructor of medicine at Harvard Medical School, describes the last decade in lung cancer diagnostics and significant therapeutic advances. He also navigates the emerging classes of drugs that are beginning to make headway in the lung cancer pipeline.

Melissa L. Johnson, MD, discusses the promise of DS-7300 in small cell lung cancer and other advanced solid tumors.

Sandip Patel, MD, an associate professor of medical oncology at University of California San Diego, explains the optimal diagnostic strategies that can be utilized to better inform biomarker-based therapies in lung cancer.

Alexander I. Spira, MD, PhD, FACP, discusses the results of the phase 1 TROPION-PanTumor01 trial in non–small cell lung cancer.

James L. Mulshine, MD, professor of internal medicine, and associate director of Institute of Translation Medicine at Rush University, discusses the benefits of establishing a timely and investigation-informed screening and referral practice for patients who are at risk for developing lung cancer.

The second part of the webinar Lung Cancer Screening and Treatment: What's Next? focuses on the review of lung cancer screening and treatment status amid the COVID-19 pandemic. Participating faculty include Albert Rizzo, MD, FCCP, FACP, FAASM; James L. Mulshine, MD; Andrea Borondy Kitts, MS, MPH; and Sandip Patel, MD.

Anish Thomas, MBBS, MD, medical oncologist, Lasker Clinical Research Scholar, Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, discusses the rationale for the phase 2 DDRiver SCLC 250 trial in relapsed, platinum-resistant small cell lung cancer.

Spanning metastatic non–small cell lung cancer, castration-resistant prostate cancer, and HER2-low breast cancer, here are 4 must-know clinical trials in Tennessee that community oncologists can now enroll their patients on.

Ben Levy, Mark Socinski, and Stephen Liu explain the various types of genetic alterations and protein expressions that are targetable in NSCLC and the crucial role of comprehensive genetic testing at the time of diagnosis and at the time of disease progression.

An increased understanding of driver gene alterations in advanced non–small cell lung cancer (NSCLC) has led to the development of targeted therapies that offer improved patient outcomes. Ben Levy, MD; Mark A. Socinski, MD; and Stephen Liu, MD, share their thoughts on the emerging treatment landscape and remaining unmet needs.

As novel therapies, new treatment strategies, and ongoing clinical trials continue to steer the path forward in lung cancer, treatment patterns for patients with non–small cell lung cancer, small cell lung cancer, and mesothelioma are continuing to evolve.

Aaron S. Mansfield, MD, discusses ongoing trials with chemoimmunotherapy in mesothelioma.